bs-0766R [Primary Antibody]
CD4 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: CD4

Immunogen Range: 231-330/457


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 12504

Swiss Prot: P06332

Source: KLH conjugated synthetic peptide derived from mouse CD4

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

Accessory protein for MHC class-II antigen/T-cell receptor interaction. May regulate T-cell activation.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
FCM(1:20-100)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 48


Cross Reactive Species: Human
Mouse
Rat
Others

Predicted Cross Reactive Species: Hamster

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Zhang, Wen, et al. "The role of CXCR3 in the induction of primary biliary cirrhosis." Clinical and Developmental Immunology 2011 (2011).Read more>>
  • Cheng, Lin, et al. "T cell immunohistochemistry refines lung transplant acute rejection diagnosis and grading." Diagnostic Pathology 8.1 (2013): 168.Read more>>
  • Tzeng, Yuan-Sheng, et al. "Hypercapnic acidosis prolongs survival of skin allografts." Journal of Surgical Research (2014).Read more>>
  • Wang, Raymond M., et al. "Humanized mouse model for assessing the human immune response to xenogeneic and allogeneic decellularized biomaterials." Biomaterials (2017).Read more>>
  • Willett, Emily S., et al. "Standardized Rat Model Testing Effects of Inflammation and Grafting on Extraction Healing." Journal of Periodontology (2017): 1-15.Read more>>
  • Matsubara et al. Immune activation during the implantation phase causes preeclampsia-like symptoms via the CD40-CD40 ligand pathway in pregnant mice. (2016) Hypertens.Re. 39:407-14Read more>>
  • Ju et al. An effective cytokine adjuvant vaccine induces autologous T-cell response against colon cancer in an animal model. (2016) BMC.Immunol. 17:31Read more>>
  • Li, TF., et al. “Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma.” Biomaterials (2018); 181: 35-52.Read more>>
  • Wan WJ et al. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy. Int J Pharm. 2019 Jul 20;566:731-744. Read more>>
  • Yuan SJ et al. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.J Nanobiotechnology. 2019 Oct 17;17(1):110. Read more>>
  • Pan Y et al. Amino-Modified Polymer Nanoparticles as Adjuvants to Activate the Complement System and to Improve Vaccine Efficacy in Vivo. Biomacromolecules. 2019 Sep 9;20(9):3575-3583.Read more>>
  • Li TF et al. Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma.Biomaterials. 2018 Oct;181:35-52.Read more>>
  • Yihan Lu? et al. Experimental evidence for alpha enolase as one potential autoantigen in the pathogenesis of both autoimmune thyroiditis and its related encephalopathy. Int Immunopharmacol. 2020 Aug;85:106563.Read more>>
  • Liu S et al. Structural characterization of a novel polysaccharide from Panax notoginseng residue and its immunomodulatory activity on bone marrow dendritic cells. Int J Biol Macromol. 2020 Oct 15;161:797-809.Read more>>
  • Xinhua Liet al. Upregulation of microRNA-219-5p relieves ulcerative colitis through balancing the differentiation of Treg/Th17 cells. Eur J Gastroenterol Hepatol. 2020 Jul;32(7):813-820.Read more>>
  • Yitian Du. et al. Engineered Microglia Potentiate the Action of Drugs against Glioma Through Extracellular Vesicles and Tunneling Nanotubes. 2021 Feb 28Read more>>
  • Jinbo Li. et al. Low dose shikonin and anthracyclines coloaded liposomes induce robust immunogenetic cell death for synergistic chemo-immunotherapy. J Control Release. 2021 Jul;335:306Read more>>
  • Weili Xu. et al. Targeted elimination of myeloid-derived suppressor cells via regulation of the STAT pathway alleviates tumor immunosuppression in neuroblastoma. Immunol Lett. 2021 Dec;240:31Read more>>
  • Yuan-Sheng Tzeng. et al. Intermittent Exposure of Hypercapnia Suppresses Allograft Rejection via Induction of Treg Differentiation and Inhibition of Neutrophil Accumulation. BIOMEDICINES. Biomedicines. 2022 Apr;10(4):836Read more>>
  • Jinbo Li. et al. Autophagy inhibition recovers deficient ICD-based cancer immunotherapy. BIOMATERIALS. 2022 Aug;287:121651Read more>>
  • Xiaoliang Hua. et al. CXCR3 antagonist AMG487 ameliorates experimental autoimmune prostatitis by diminishing Th1 cell differentiation and inhibiting macrophage M1 phenotypic activation. PROSTATE. 2022 Jun 14Read more>>
  • Dr. Sakura Uto. et al. Subcutaneously Transplanted Fresh Cartilage in Allogeneic and Xenogeneic Immunocompetent Mouse. Tissue Engineering Part A. 2023 Aug 07Read more>>
  • Peng Xue. et al. Fe3+ mediated shikonin and PPA coloaded liposomes induce robust immunogenic cell death by integrating ROS enhancement and GSH depletion. INT J PHARMACEUT. 2024 Jan;649:123657Read more>>
  • Lei Wang. et al. STING Agonist-Loaded Nanoparticles Promotes Positive Regulation of Type I Interferon-Dependent Radioimmunotherapy in Rectal Cancer. ADV SCI. 2023 Dec;:2307858Read more>>
  • Tianyi Cui. et al. Polygonatum odoratum polysaccharide ameliorates the allergic airway inflammation through regulating the gut microbiota and inhibiting gut-lung migration of ILC2s. J FUNCT FOODS. 2024 Jul;118:106276Read more>>
  • Jie Zhang. et al. CCR7 and CD48 as Predicted Targets in Acute Rejection Related to M1 Macrophage after Pediatric Kidney Transplantation. J IMMUNOL RES. 2024 Jun;2024(1):6908968Read more>>
VALIDATION IMAGES

Formalin-fixed and paraffin embedded rat skin labeled with Rabbit Anti-CD4 Polyclonal Antibody, Unconjugated(bs-0766R) 1:300 followed by conjugation to the secondary antibody and DAB staining.


Formalin-fixed and paraffin embedded mouse kidney cells labeled with Rabbit Anti-CD4 Polyclonal Antibody, Unconjugated (bs-0766R) 1:200 followed by conjugation to the secondary antibody and DAB staining.


Formalin-fixed and paraffin embedded Lymphocytes labeled with (bs-0766R) Rabbit Anti-CD4 Polyclonal Antibody, Unconjugated followed by incubation with a conjugated secondary antibody.


Formalin-fixed and paraffin embedded Lymphocytes labeled with Rabbit Anti-CD4 Polyclonal Antibody, Unconjugated(bs-0766R) followed by incubation with a conjugated secondary antibody and DAPI staining.


Paraformaldehyde-fixed, paraffin embedded rat spleen; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with CD4 Polyclonal Antibody, Unconjugated (bs-0766R) at 1:400 overnight at 4°C, followed by a conjugated secondary for 20 minutes and DAB staining.


Mouse spleen lysates probed with CD4 Polyclonal Antibody, Unconjugated (bs-0766R) at 1:500 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:10000 for 60 min at 37˚C.


Lane 1: Mouse Lymph Node; Lane 2: Mouse Spleen; 40ug loaded into each lane; Probed with CD4 Polyclonal Antibody, Unconjugated (bs-0766R) at 1:300 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:10000 for 60 min at 37˚C.


Tissue/cell: Mouse Lymphoma tissue; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum) at 37℃ for 20 min; Incubation: CD4 Polyclonal Antibody, Unconjugated (bs-0766R) 1:200, overnight at 4°C, followed by incubation with secondary antibody and DAB staining


Mouse Spleen Cells were fixed with 70% methanol (Overnight at 4℃). The cells were then incubated in 1X PBS / 2% BSA / 10% goat serum to block non-specific protein-protein interactions for 15 min at room temperature. Primary incubation with CD4 Polyclonal Antibody, PE-Conjugated (bs-0766R-PE) at 1:100 for 30 minutes at room temp. The graph compares the primary antibody (green) to unstained cells (dark blue) and isotype control (orange).


Mouse spleen cells(black) were incubated in 5% BSA blocking buffer for 30 min at room temperature. Cells were then stained with CD4 Polyclonal Antibody(bs-0766R)at 1:50 dilution in blocking buffer and incubated for 30 min at room temperature, washed twice with 2% BSA in PBS, followed by secondary antibody(blue) incubation for 40 min at room temperature. Acquisitions of 20,000 events were performed. Cells stained with primary antibody (green), and isotype control (orange).


Hamster lung IF staining


Lane 1: Human HL-60 cell lysates; Lane 2: Human MOLT4 cell lysates; Lane 3: Human Jurkat cell lysates; Lane 4: Human Raji cell lysates probed with CD4 Polyclonal Antibody, Unconjugated (bs-0766R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.